Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Efficacy of Apramycin against Multidrug-Resistant Acinetobacter baumannii in the Murine Neutropenic Thigh Model.

Kang AD, Smith KP, Berg AH, Truelson KA, Eliopoulos GM, McCoy C, Kirby JE.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02585-17. doi: 10.1128/AAC.02585-17. Print 2018 Apr.

2.

Invitro Apramycin Activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

Kang AD, Smith KP, Eliopoulos GM, Berg AH, McCoy C, Kirby JE.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):188-191. doi: 10.1016/j.diagmicrobio.2017.03.006. Epub 2017 Mar 16.

PMID:
28341099
3.

Susceptibility of Multidrug-Resistant Gram-Negative Urine Isolates to Oral Antibiotics.

Hirsch EB, Zucchi PC, Chen A, Raux BR, Kirby JE, McCoy C, Eliopoulos GM.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):3138-40. doi: 10.1128/AAC.02961-15. Print 2016 May.

4.

Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.

Hirsch EB, Raux BR, Zucchi PC, Kim Y, McCoy C, Kirby JE, Wright SB, Eliopoulos GM.

Int J Antimicrob Agents. 2015 Dec;46(6):642-7. doi: 10.1016/j.ijantimicag.2015.08.012. Epub 2015 Sep 30.

PMID:
26498988
5.

Impact of daptomycin resistance on Staphylococcus aureus virulence.

Cameron DR, Mortin LI, Rubio A, Mylonakis E, Moellering RC Jr, Eliopoulos GM, Peleg AY.

Virulence. 2015;6(2):127-31. doi: 10.1080/21505594.2015.1011532.

6.

An enabling act.

Chalkias S, Doweiko JP, Eliopoulos GM.

Open Forum Infect Dis. 2014 Apr 29;1(1):ofu008. doi: 10.1093/ofid/ofu008. eCollection 2014 Mar.

7.

In memoriam: Robert C. Moellering, Jr.

Rice LB, Eliopoulos GM, Jacoby GA.

Antimicrob Agents Chemother. 2014 Jul;58(7):3583-4. doi: 10.1128/AAC.03199-14. Epub 2014 May 5. No abstract available.

8.

Daptomycin In Vitro Activity against Methicillin-Resistant Staphylococcus aureus Is Enhanced by d-Cycloserine in a Mechanism Associated with a Decrease in Cell Surface Charge.

Gasch O, Pillai SK, Dakos J, Miyakis S, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2013 Sep;57(9):4537-4539. doi: 10.1128/AAC.00799-13. Epub 2013 Jun 24.

9.

Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus.

Cameron DR, Ward DV, Kostoulias X, Howden BP, Moellering RC Jr, Eliopoulos GM, Peleg AY.

J Infect Dis. 2012 Jun;205(11):1677-87. doi: 10.1093/infdis/jis252. Epub 2012 Apr 5.

10.

Whole genome characterization of the mechanisms of daptomycin resistance in clinical and laboratory derived isolates of Staphylococcus aureus.

Peleg AY, Miyakis S, Ward DV, Earl AM, Rubio A, Cameron DR, Pillai S, Moellering RC Jr, Eliopoulos GM.

PLoS One. 2012;7(1):e28316. doi: 10.1371/journal.pone.0028316. Epub 2012 Jan 6.

11.

Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.

Joukhadar C, Pillai S, Wennersten C, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2010 Feb;54(2):773-7. doi: 10.1128/AAC.00348-09. Epub 2009 Nov 23.

12.

Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States.

Galloway-Peña JR, Nallapareddy SR, Arias CA, Eliopoulos GM, Murray BE.

J Infect Dis. 2009 Nov 15;200(10):1566-73. doi: 10.1086/644790.

13.

Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.

Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW.

Clin Infect Dis. 2009 Oct 15;49(8):1169-74. doi: 10.1086/605636.

PMID:
19769538
14.

Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria.

Eliopoulos GM.

J Infect. 2009 Sep;59 Suppl 1:S17-24. doi: 10.1016/S0163-4453(09)60004-9. Review.

PMID:
19766885
15.

Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics.

Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC Jr, Mylonakis E.

Antimicrob Agents Chemother. 2009 Jun;53(6):2605-9. doi: 10.1128/AAC.01533-08. Epub 2009 Mar 30.

16.

Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection.

Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr, Eliopoulos GM.

J Infect Dis. 2009 Feb 15;199(4):532-6. doi: 10.1086/596511.

17.

Utility of peptide nucleic acid fluorescence in situ hybridization for rapid detection of Acinetobacter spp. and Pseudomonas aeruginosa.

Peleg AY, Tilahun Y, Fiandaca MJ, D'Agata EM, Venkataraman L, Moellering RC Jr, Eliopoulos GM.

J Clin Microbiol. 2009 Mar;47(3):830-2. doi: 10.1128/JCM.01724-08. Epub 2008 Dec 30.

18.

Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans.

Peleg AY, Tampakakis E, Fuchs BB, Eliopoulos GM, Moellering RC Jr, Mylonakis E.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14585-90. doi: 10.1073/pnas.0805048105. Epub 2008 Sep 15.

19.

Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

Gqada Z, Marais B, Wasserman E, Bamford C, Orth H, Sakoulas G, Rose W, Rybak MJ, Pillai S, Alder J, Moellering RC Jr, Eliopoulos GM.

J Clin Microbiol. 2008 Jul;46(7):2471; author reply 2471-2. doi: 10.1128/JCM.00519-08. No abstract available.

20.

Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.

Sakoulas G, Rose W, Rybak MJ, Pillai S, Alder J, Moellering RC Jr, Eliopoulos GM.

J Clin Microbiol. 2008 Jan;46(1):220-4. Epub 2007 Nov 14.

21.

Persistence of rRNA operon mutated copies and rapid re-emergence of linezolid resistance in Staphylococcus aureus.

Tsakris A, Pillai SK, Gold HS, Thauvin-Eliopoulos C, Venkataraman L, Wennersten C, Moellering RC Jr, Eliopoulos GM.

J Antimicrob Chemother. 2007 Sep;60(3):649-51. Epub 2007 Jul 10.

PMID:
17623697
22.

Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.

Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2007 Jun;51(6):2223-5. Epub 2007 Apr 2.

23.

Vancomycin-tolerant Streptococcus pneumoniae in Korea.

Sung H, Shin HB, Kim MN, Lee K, Kim EC, Song W, Jeong SH, Lee WG, Park YJ, Eliopoulos GM.

J Clin Microbiol. 2006 Oct;44(10):3524-8.

24.

Enterococci: on the back burner but still simmering.

Eliopoulos GM.

Curr Infect Dis Rep. 2006 Sep;8(5):333-6. No abstract available.

PMID:
16934190
25.

Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.

Sakoulas G, Alder J, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM.

Antimicrob Agents Chemother. 2006 Apr;50(4):1581-5.

26.

Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.

Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM.

J Antimicrob Chemother. 2006 Apr;57(4):699-704. Epub 2006 Feb 7.

PMID:
16464892
27.

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.

Sakoulas G, Moellering RC Jr, Eliopoulos GM.

Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S40-50. Review.

PMID:
16323119
28.

Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

Eliopoulos GM.

Eur J Clin Microbiol Infect Dis. 2005 Dec;24(12):826-31. Review.

PMID:
16315008
29.

In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.

Eliopoulos GM, Ferraro MJ, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 2005 Jul;49(7):3034-9.

30.

Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function.

Sakoulas G, Eliopoulos GM, Fowler VG Jr, Moellering RC Jr, Novick RP, Lucindo N, Yeaman MR, Bayer AS.

Antimicrob Agents Chemother. 2005 Jul;49(7):2687-92.

31.

Safety and efficacy of glycopeptide antibiotics.

Finch RG, Eliopoulos GM.

J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii5-13. Review.

PMID:
15750036
32.

Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus.

Meka VG, Gold HS, Cooke A, Venkataraman L, Eliopoulos GM, Moellering RC Jr, Jenkins SG.

J Antimicrob Chemother. 2004 Oct;54(4):818-20. Epub 2004 Sep 3.

PMID:
15347637
33.

Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein.

Fowler VG Jr, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, Cabell CH, Stryjewski ME, Eliopoulos GM, Reller LB, Corey GR, Jones T, Lucindo N, Yeaman MR, Bayer AS.

J Infect Dis. 2004 Sep 15;190(6):1140-9. Epub 2004 Aug 12.

PMID:
15319865
34.

Effects of glucose on fsr-mediated biofilm formation in Enterococcus faecalis.

Pillai SK, Sakoulas G, Eliopoulos GM, Moellering RC Jr, Murray BE, Inouye RT.

J Infect Dis. 2004 Sep 1;190(5):967-70. Epub 2004 Jul 27.

PMID:
15295702
35.

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.

Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr.

Clin Infect Dis. 2004 Jun 15;38(12):1700-5. Epub 2004 May 21.

PMID:
15227615
36.

Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.

Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, Eliopoulos GM, Moellering RC Jr, Gold HS.

J Infect Dis. 2004 Jul 15;190(2):311-7. Epub 2004 Jun 9.

PMID:
15216466
37.

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM.

J Clin Microbiol. 2004 Jun;42(6):2398-402.

38.

Quinolone resistance mechanisms in pneumococci.

Eliopoulos GM.

Clin Infect Dis. 2004 May 15;38 Suppl 4:S350-6.

PMID:
15127369
39.

Current and new antimicrobial agents.

Eliopoulos GM.

Am Heart J. 2004 Apr;147(4):587-92.

PMID:
15077072
40.

Introduction of erm(C) into a linezolid- and methicillin-resistant Staphylococcus aureus does not restore linezolid susceptibility.

Sakoulas G, Gold HS, Venkataraman L, Moellering RC Jr, Ferraro MJ, Eliopoulos GM.

J Antimicrob Chemother. 2003 Apr;51(4):1039-41. No abstract available.

PMID:
12728937
41.

Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT.

Antimicrob Agents Chemother. 2003 May;47(5):1714-8.

42.

Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C, DeGirolami PC, Schwaber MJ, Gold HS.

J Infect Dis. 2003 Mar 15;187(6):929-38. Epub 2003 Mar 6.

PMID:
12660939
43.

Quinupristin-dalfopristin and linezolid: evidence and opinion.

Eliopoulos GM.

Clin Infect Dis. 2003 Feb 15;36(4):473-81. Epub 2003 Jan 31. Review.

PMID:
12567306
44.

Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.

Pillai SK, Sakoulas G, Wennersten C, Eliopoulos GM, Moellering RC Jr, Ferraro MJ, Gold HS.

J Infect Dis. 2002 Dec 1;186(11):1603-7. Epub 2002 Nov 4.

PMID:
12447736
45.

In vitro activity of the new oxazolidinone AZD2563 against Enterococci.

Eliopoulos GM, Wennersten CB, Moellering RC Jr.

Antimicrob Agents Chemother. 2002 Oct;46(10):3273-5.

46.
47.

Prevalence of the fsr locus in Enterococcus faecalis infections.

Pillai SK, Sakoulas G, Gold HS, Wennersten C, Eliopoulos GM, Moellering RC Jr, Inouye RT.

J Clin Microbiol. 2002 Jul;40(7):2651-2.

48.

Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin.

Sakoulas G, Eliopoulos GM, Moellering RC Jr, Wennersten C, Venkataraman L, Novick RP, Gold HS.

Antimicrob Agents Chemother. 2002 May;46(5):1492-502.

49.
50.

Quinolones and false-positive urine screening for opiates by immunoassay technology.

Baden LR, Horowitz G, Jacoby H, Eliopoulos GM.

JAMA. 2001 Dec 26;286(24):3115-9.

PMID:
11754677

Supplemental Content

Loading ...
Support Center